A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma. READ MORE

News

Combination therapy involving a novel treatment is associated with reduced risk of death and improved progression-free survival (PFS) in patients with advanced multiple myeloma, according to research presented at the 22nd Congress of the European Hematology Association (June 22-25, 2017; Madrid, Spain).

-----

Related Content

READ MORE

Multiple prognostic tools help risk stratify older patients with multiple myeloma and predict treatment-specific survival, according to data that will be presented at the 22nd Congress of the European Hematology Association (June 22-25, 2017; Madrid, Spain).

-----

Related Content

READ MORE

Adding a targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma is a safe and efficacious alternative to autologous stem cell transplantation (ASCT) with KRd, according to research presented at the 2017 ASCO Annual Meeting (June2-6, 2017; Chicago, IL).

-----

Related Content

READ MORE

Survivors of Hodgkin lymphoma with a family history of cancer have a 1.3-fold higher risk of developing a second cancer, according to research published in the Journal of Clinical Oncology (May 2017;35[14]:1584-1590).

-----

Related Content

READ MORE